المؤلفون: Liu H; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Pan D; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Yao Z; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Wang H; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Li Y; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Qin X; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Qu P; Department of Gastroenterology, The second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Tang J; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Electronic address: tm350347@163.com., Han Z; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. Electronic address: cnhzxyq@163.com.

المصدر: International immunopharmacology [Int Immunopharmacol] 2024 Sep 30; Vol. 139, pp. 112635. Date of Electronic Publication: 2024 Jul 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Pancreatic Neoplasms*/drug therapy , Pancreatic Neoplasms*/mortality , Gemcitabine* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Deoxycytidine*/analogs & derivatives , Deoxycytidine*/therapeutic use , Deoxycytidine*/administration & dosage , Deoxycytidine*/adverse effects , Paclitaxel*/therapeutic use , Paclitaxel*/administration & dosage , Paclitaxel*/adverse effects , Albumins*/therapeutic use , Albumins*/administration & dosage , Albumins*/adverse effects , Indoles*/therapeutic use , Indoles*/administration & dosage , Indoles*/adverse effects , Quinolines*/therapeutic use , Quinolines*/administration & dosage , Quinolines*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Adult ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/administration & dosage ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Treatment Outcome

المؤلفون: Urabe M; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan., Ikezawa K; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan. ikezawa-ke@oici.jp., Seiki Y; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan., Watsuji K; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan., Kawamoto Y; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan., Hirao T; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan., Kai Y; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan., Takada R; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan., Yamai T; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan., Mukai K; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan., Nakabori T; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan., Uehara H; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan., Nagata S; Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan., Ohkawa K; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan.

المصدر: Scientific reports [Sci Rep] 2024 Sep 20; Vol. 14 (1), pp. 21953. Date of Electronic Publication: 2024 Sep 20.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

مواضيع طبية MeSH: Pancreatic Neoplasms*/drug therapy , Pancreatic Neoplasms*/pathology , Pancreatic Neoplasms*/metabolism , Pancreatic Neoplasms*/mortality , Deoxycytidine*/analogs & derivatives , Deoxycytidine*/therapeutic use , Deoxycytidine*/administration & dosage , Gemcitabine* , Paclitaxel*/administration & dosage , Paclitaxel*/therapeutic use , Albumins*/administration & dosage , Albumins*/metabolism , Myeloid Cell Leukemia Sequence 1 Protein*/metabolism , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Biomarkers, Tumor*/metabolism, Humans ; Male ; Female ; Aged ; Middle Aged ; Retrospective Studies ; Prognosis ; Neoplasm Metastasis ; Adult ; Treatment Outcome ; Aged, 80 and over ; Liver Neoplasms/drug therapy ; Liver Neoplasms/secondary ; Liver Neoplasms/metabolism ; Liver Neoplasms/pathology

المؤلفون: Budillon A; Scientific Directorate, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy. a.budillon@istitutotumori.na.it., Leone A; Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Passaro E; Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Silvestro L; Experimental Clinical Abdominal Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Foschini F; Experimental Clinical Abdominal Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Iannelli F; Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Roca MS; Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Macchini M; Department of Medical Oncology, University 'Vita-Salute San Raffaele', IRCCS- Ospedale San Raffaele, Milan, Italy., Bruzzese F; Animal Facility Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Garcia Bermejo ML; Biomarkers and Therapeutic Targets Group, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain., Rodriguez Garrote M; Biomarkers and Personalized Approach to Cancer Group (BIOPAC), Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain., Tortora G; Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.; Medical Oncology, Department of Translational Medicine, Catholic University of the Sacred Heart, Rome, Italy., Milella M; Section of Innovation Biomedicines-Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy., Reni M; Department of Medical Oncology, University 'Vita-Salute San Raffaele', IRCCS- Ospedale San Raffaele, Milan, Italy., Fuchs C; EURORDIS - Rare Disease Europe, Paris, France., Hewitt E; Beacon: for rare diseases, Cambridge, UK., Kubiak C; ECRIN - European Clinical Research Infrastructure Network-European Research Infrastructure Consortium, Paris, France., Di Gennaro E; Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Giannarelli D; Facility of Epidemiology and Biostatistics, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Avallone A; Experimental Clinical Abdominal Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy. a.avallone@istitutotumori.na.it.

المصدر: BMC cancer [BMC Cancer] 2024 Sep 19; Vol. 24 (1), pp. 1167. Date of Electronic Publication: 2024 Sep 19.

نوع المنشور: Journal Article; Clinical Trial Protocol; Multicenter Study; Clinical Trial, Phase II; Randomized Controlled Trial

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Valproic Acid*/therapeutic use , Valproic Acid*/administration & dosage , Pancreatic Neoplasms*/drug therapy , Pancreatic Neoplasms*/pathology , Simvastatin*/administration & dosage , Simvastatin*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Gemcitabine* , Deoxycytidine*/analogs & derivatives , Deoxycytidine*/administration & dosage , Deoxycytidine*/therapeutic use , Paclitaxel*/administration & dosage , Paclitaxel*/therapeutic use , Albumins*/administration & dosage , Albumins*/therapeutic use, Humans ; Female ; Male ; Carcinoma, Pancreatic Ductal/drug therapy ; Carcinoma, Pancreatic Ductal/pathology ; Middle Aged ; Aged ; Drug Repositioning/methods ; Adult

المؤلفون: Greenhalgh DG; Burn Department, Shriners Children's Northern California, 2425 Stockton Boulevard, Sacramento, CA 95817, USA; Emeritus, Department of Surgery, University of California, Davis, CA, USA. Electronic address: dggreenhalgh@ucdavis.edu.

المصدر: Advances in surgery [Adv Surg] 2024 Sep; Vol. 58 (1), pp. 1-17. Date of Electronic Publication: 2024 May 08.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 0045335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0555 (Electronic) Linking ISSN: 00653411 NLM ISO Abbreviation: Adv Surg Subsets: MEDLINE

مواضيع طبية MeSH: Burns*/therapy , Resuscitation*/methods , Fluid Therapy*/methods , Albumins*/therapeutic use , Albumins*/administration & dosage, Humans ; Crystalloid Solutions/administration & dosage ; Crystalloid Solutions/therapeutic use ; Colloids/therapeutic use ; Colloids/administration & dosage ; Isotonic Solutions/therapeutic use ; Isotonic Solutions/administration & dosage

المؤلفون: Conner JA; Department of Horticulture and Institute of Plant Breeding, Genetics and Genomics, University of Georgia, Tifton, Georgia, USA., Guimaraes LA; Department of Horticulture and Institute of Plant Breeding, Genetics and Genomics, University of Georgia, Tifton, Georgia, USA., Zhang Z; Department of Horticulture and Institute of Plant Breeding, Genetics and Genomics, University of Georgia, Tifton, Georgia, USA., Marasigan K; Department of Horticulture and Institute of Plant Breeding, Genetics and Genomics, University of Georgia, Tifton, Georgia, USA., Chu Y; Department of Horticulture and Institute of Plant Breeding, Genetics and Genomics, University of Georgia, Tifton, Georgia, USA., Korani W; HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA., Ozias-Akins P; Department of Horticulture and Institute of Plant Breeding, Genetics and Genomics, University of Georgia, Tifton, Georgia, USA.

المصدر: Plant biotechnology journal [Plant Biotechnol J] 2024 Sep; Vol. 22 (9), pp. 2438-2440. Date of Electronic Publication: 2024 May 07.

نوع المنشور: Letter; Journal Article

بيانات الدورية: Publisher: Wiley on behalf of the Society for Experimental Biology, Association of Applied Biologists Country of Publication: England NLM ID: 101201889 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1467-7652 (Electronic) Linking ISSN: 14677644 NLM ISO Abbreviation: Plant Biotechnol J Subsets: MEDLINE

مواضيع طبية MeSH: Arachis*/genetics , Arachis*/metabolism , 2S Albumins, Plant*/genetics , 2S Albumins, Plant*/metabolism , Gene Silencing*, Plants, Genetically Modified/genetics

المؤلفون: Tezuka S; Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan. Electronic address: tezuka-shun@kcch.jp., Ozaka M; Japanese Foundation for Cancer Research, Tokyo, Japan., Furuse J; Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan., Yokoyama M; JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan., Uemura K; JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan., Sano Y; JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan., Nakachi K; Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Japan., Imaoka H; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Unno M; Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan., Shirakawa H; Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Japan., Shimizu S; Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan., Kato N; Department of Gastroenterology, Chiba University, Chiba, Japan., Kojima Y; Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan., Sano K; Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan., Kobayashi S; Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan., Terashima T; Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan., Morizane C; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan., Ikeda M; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Ueno M; Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.

المصدر: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] [Pancreatology] 2024 Sep; Vol. 24 (6), pp. 909-916. Date of Electronic Publication: 2024 Jul 16.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II

بيانات الدورية: Publisher: Country of Publication: Switzerland NLM ID: 100966936 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1424-3911 (Electronic) Linking ISSN: 14243903 NLM ISO Abbreviation: Pancreatology Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Pancreatic Neoplasms*/drug therapy , Pancreatic Neoplasms*/pathology , Paclitaxel*/administration & dosage , Paclitaxel*/therapeutic use , Deoxycytidine*/analogs & derivatives , Deoxycytidine*/administration & dosage , Deoxycytidine*/therapeutic use , Fluorouracil*/therapeutic use , Fluorouracil*/administration & dosage , Gemcitabine* , Oxaliplatin*/therapeutic use , Oxaliplatin*/administration & dosage , Irinotecan*/therapeutic use , Irinotecan*/administration & dosage , Leucovorin*/therapeutic use , Leucovorin*/administration & dosage , Albumins*/administration & dosage , Albumins*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Aged ; Prognosis ; Adult ; Treatment Outcome

المؤلفون: Liu D; Amsterdam UMC Location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands; Amsterdam UMC location University of Amsterdam, Department of Medical Oncology, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands; Cancer Center Amsterdam, Cancer Biology, Amsterdam, the Netherlands., Guo L; Amsterdam UMC location University of Amsterdam, Department Experimental Immunology, Amsterdam Infection and Immunity Center, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands., Waasdorp C; Amsterdam UMC Location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands; Cancer Center Amsterdam, Cancer Biology, Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands., Meijer SL; Amsterdam UMC Location University of Amsterdam, Department of Pathology, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands., Bootsma S; Amsterdam UMC Location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands; Amsterdam UMC location University of Amsterdam, Department of Medical Oncology, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands; Cancer Center Amsterdam, Cancer Biology, Amsterdam, the Netherlands., Oyarce C; Amsterdam UMC Location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands; Cancer Center Amsterdam, Cancer Biology, Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands., Bijlsma MF; Amsterdam UMC Location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands; Cancer Center Amsterdam, Cancer Biology, Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands., van Laarhoven HWM; Amsterdam UMC location University of Amsterdam, Department of Medical Oncology, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands; Cancer Center Amsterdam, Cancer Biology, Amsterdam, the Netherlands. Electronic address: h.vanlaarhoven@amsterdamumc.nl.

المصدر: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Sep; Vol. 178, pp. 117261. Date of Electronic Publication: 2024 Aug 05.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 8213295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1950-6007 (Electronic) Linking ISSN: 07533322 NLM ISO Abbreviation: Biomed Pharmacother Subsets: MEDLINE

مواضيع طبية MeSH: Paclitaxel*/pharmacology , Paclitaxel*/administration & dosage , Paclitaxel*/therapeutic use , Hyaluronoglucosaminidase*/administration & dosage , Esophageal Neoplasms*/drug therapy , Esophageal Neoplasms*/pathology , Angiogenesis Inhibitors*/pharmacology , Angiogenesis Inhibitors*/administration & dosage , Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/pathology , Xenograft Model Antitumor Assays* , Albumins*/pharmacology , Albumins*/administration & dosage , Neovascularization, Pathologic*/drug therapy , Neovascularization, Pathologic*/pathology, Animals ; Humans ; Mice ; Hyaluronic Acid/pharmacology ; Mice, Nude ; Female ; Angiogenesis ; Antibodies, Monoclonal

المؤلفون: Chen CT; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California., Khanna V; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California., Kummar S; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.; Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon., Abdul-Karim RM; NEXT Oncology, San Antonio, Texas., Sommerhalder D; NEXT Oncology, San Antonio, Texas., Tolcher AW; NEXT Oncology, San Antonio, Texas., Ueno NT; University of Texas MD Anderson Cancer Center, Houston, Texas., Davis SL; University of Colorado Cancer Center, Aurora, Colorado., Orr DW; Mary Crowley Cancer Research, Dallas, Texas., Hamilton E; Sarah Cannon Research Institute, Nashville, Tennessee., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida., Spira AI; Virginia Cancer Specialists, Fairfax, Virginia., Jauhari S; Florida Cancer Specialists/Sarah Cannon Research Institute, Lake Mary, Florida., Florou V; 1Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Duff M; ORIC Pharmaceuticals, South San Francisco, California., Xu R; ORIC Pharmaceuticals, South San Francisco, California., Wang J; ORIC Pharmaceuticals, South San Francisco, California., Barkund SR; ORIC Pharmaceuticals, South San Francisco, California., Zhou H; ORIC Pharmaceuticals, South San Francisco, California., Pankov A; ORIC Pharmaceuticals, South San Francisco, California., Kong W; ORIC Pharmaceuticals, South San Francisco, California., Jahchan NS; ORIC Pharmaceuticals, South San Francisco, California., Jackson EL; ORIC Pharmaceuticals, South San Francisco, California., Sun JD; ORIC Pharmaceuticals, South San Francisco, California., Junttila MR; ORIC Pharmaceuticals, South San Francisco, California., Multani PS; ORIC Pharmaceuticals, South San Francisco, California., Daemen A; ORIC Pharmaceuticals, South San Francisco, California., Chow Maneval E; ORIC Pharmaceuticals, South San Francisco, California., Munster PN; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.

المصدر: Cancer research communications [Cancer Res Commun] 2024 Sep 01; Vol. 4 (9), pp. 2415-2426.

نوع المنشور: Journal Article; Clinical Trial, Phase I

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE

مواضيع طبية MeSH: Paclitaxel*/therapeutic use , Paclitaxel*/administration & dosage , Paclitaxel*/pharmacology , Neoplasms*/drug therapy , Neoplasms*/pathology , Receptors, Glucocorticoid*/antagonists & inhibitors , Receptors, Glucocorticoid*/metabolism , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Albumins*/administration & dosage , Albumins*/therapeutic use , Albumins*/pharmacology, Humans ; Female ; Male ; Middle Aged ; Aged ; Animals ; Adult ; Mice ; Xenograft Model Antitumor Assays ; Drug Resistance, Neoplasm/drug effects ; Cell Line, Tumor

المؤلفون: Portefaix A; Clinical Investigation Center, Hospices Civils de Lyon, Lyon Bron, France aurelie.portefaix@chu-lyon.fr.; EMET LBBE, Université Claude Bernard Lyon 1, Villeurbanne, France., Dhelens C; Pharmacie FRIPHARM, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France., Recher M; Services de Réanimation Pédiatrique, CHU Lille, F59000-Lille, France.; METRICS, Universite Lille Nord de France, Villeneuve-d'Ascq, Hauts-de-France, France., Cour-Andlauer F; Réanimation Pédiatrique, Centre Hospitalier Universitaire de Lyon, Bron, France., Naudin J; Service de Réanimation Pédiatrique, Hôpital Universitaire Robert-Debré, Paris, Île-de-France, France., Mortamet G; Pediatric Intensive Care Unit, Necker Hospital, Paris, France., Joram N; Réanimation Pédiatrique, CHU Nantes, Nantes, Pays de la Loire, France., Tissières P; Paediatric Intensive Care Unit, Hospital Bicetre, Le Kremlin-Bicetre, Île-de-France, France.; Institute for Integrative Cell Biology, Gif-sur-Yvette, Île-de-France, France., Ginhoux T; Clinical Investigation Center, Hospices Civils de Lyon, Lyon Bron, France., Kassai B; Clinical Investigation Center, Hospices Civils de Lyon, Lyon Bron, France.; Université Lyon 1, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Villeurbanne, France., Boutitie F; Biostatistics, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France., Maucort-Boulch D; Biostatistics, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France., Javouhey E; Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France.; EA 7426 Joint Research Unit HCL-bioMérieux, Université Claude Bernard Lyon 1, Villeurbanne, Auvergne-Rhône-Alpes, France.

المصدر: Archives of disease in childhood [Arch Dis Child] 2024 Aug 16; Vol. 109 (9), pp. 717-723. Date of Electronic Publication: 2024 Aug 16.

نوع المنشور: Journal Article; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: BMJ Pub. Group [etc.] Country of Publication: England NLM ID: 0372434 Publication Model: Electronic Cited Medium: Internet ISSN: 1468-2044 (Electronic) Linking ISSN: 00039888 NLM ISO Abbreviation: Arch Dis Child Subsets: MEDLINE

مواضيع طبية MeSH: Feasibility Studies* , Immunoglobulins, Intravenous*/administration & dosage , Immunoglobulins, Intravenous*/adverse effects , Immunoglobulins, Intravenous*/therapeutic use , Shock, Septic*/drug therapy , Shock, Septic*/mortality , Albumins*/administration & dosage , Albumins*/therapeutic use , Albumins*/adverse effects, Humans ; Child ; Male ; Female ; Double-Blind Method ; Child, Preschool ; Adolescent ; Treatment Outcome ; Infant

المؤلفون: Terashima Y; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Matsumoto M; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Ozaki S; Department of Dermatology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Nakagawa M; Department of Dermatology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Nakagome S; Department of Gastroenterology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Terasaki Y; Department of Analytic Human Pathology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Iida H; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Mitsugi R; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Kuramochi E; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Okada N; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Inoue T; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Matsuki S; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Kitagawa S; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Fukuizumi A; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Onda N; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Takeuchi S; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Miyanaga A; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Kasahara K; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan., Seike M; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

المصدر: Frontiers in immunology [Front Immunol] 2024 Aug 14; Vol. 15, pp. 1370972. Date of Electronic Publication: 2024 Aug 14 (Print Publication: 2024).

نوع المنشور: Case Reports; Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Carboplatin*/adverse effects , Carboplatin*/administration & dosage , Carboplatin*/therapeutic use , Paclitaxel*/adverse effects , Paclitaxel*/administration & dosage , Paclitaxel*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Lung Neoplasms*/drug therapy , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Carcinoma, Squamous Cell*/drug therapy , Albumins*/adverse effects , Albumins*/administration & dosage, Humans ; Male ; Aged ; IgA Vasculitis/chemically induced ; IgA Vasculitis/diagnosis ; Immunoglobulin A ; Immune Checkpoint Inhibitors/adverse effects